KEROS THERAPEUTICS IN

Keros Therapeutics Presents Results from Preclinical Studies of KER-050 and ALK2 Inhibitors at the European School of Haematology (ESH) 2nd Translational Research E-Conference

05 مارس 2021 08:00:00 بحسب Nasdaq GlobeNewswire

Keros Therapeutics to Present at the H.C. Wainwright Global Life Sciences 2021 Virtual Conference

02 مارس 2021 08:00:02 بحسب Nasdaq GlobeNewswire

Keros Therapeutics to Present at the 10th Annual SVB Leerink Global Healthcare Conference

17 فبراير 2021 08:00:01 بحسب Nasdaq GlobeNewswire